Skip Navigation
 
 
 
 
 
Print This Page
Share this page: More
 

Search Results

Title:
J1214, A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or microsatellite instability phenotype
Protocol Number:
J1214
Phase:
Phase II
Physician:
Nilofer Azad
Purpose:
Determine the efficacy of combination gemcitabine and docetaxel chemotherapy in the treatment of metastatic colorectal cancer with CHFR and/or MSI phenotype
Eligibility:
-Adults with histologically documented metastatic colorectal adenocarcinoma with methylated CHFR and/or microsatellite instability phenotype that have relapsed or are refractory to one or more line(s) of standard therapy-Patients must be off prior chemotherapy, radiation therapy, hormonal therapy, or biological therapy for at least 4 weeks.-ECOG performance status 0 or 1-Adequate organ and marrow function
Treatment:
Patients will receive intravenous gemcitabine 800mg/m2 on days 1 and 8 and docetaxel 60mg/m2 on day 8 of each 21 day cycle. Patients will receive filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle. Patients will be evaluated for toxicity prior to receiving each cycle and every 6 weeks for response using RECIST criteria 1.0.
Population:
Adult
Last Update
09/16/2014 04:03 AM
 

Read Our Blogs
Cancer Matters: timely topics
Our Cancer: for caregivers

 

Cancer Dictionary

NCI Dictionary of Cancer Terms, a resource with more than 6,000 terms related to cancer and medicine.

Traveling for care?

blue suitcase

Whether crossing the country or the globe, we make it easy to access world-class care at Johns Hopkins.

Maryland 410-955-5222
U.S. 410-955-5222
International +1-410-614-6424

NCI CCC

 
 
 
 
 

© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.

Privacy Policy and Disclaimer